These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

526 related items for PubMed ID: 33885818

  • 1. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways.
    Acharya B, Chaijaroenkul W, Na-Bangchang K.
    J Pharm Pharmacol; 2021 Aug 12; 73(9):1191-1200. PubMed ID: 33885818
    [Abstract] [Full Text] [Related]

  • 2. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
    Yothaisong S, Dokduang H, Techasen A, Namwat N, Yongvanit P, Bhudhisawasdi V, Puapairoj A, Riggins GJ, Loilome W.
    Tumour Biol; 2013 Dec 12; 34(6):3637-48. PubMed ID: 23832540
    [Abstract] [Full Text] [Related]

  • 3. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H, Zhang J, Zhang Y, Feng Q, Wang H, Li G, Jiang W, Li X.
    Gene; 2019 May 25; 698():50-60. PubMed ID: 30822475
    [Abstract] [Full Text] [Related]

  • 4. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M.
    Int J Cancer; 2013 Nov 25; 133(9):2065-76. PubMed ID: 23588885
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
    Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN.
    Oncotarget; 2014 May 15; 5(9):2372-89. PubMed ID: 24796583
    [Abstract] [Full Text] [Related]

  • 6. Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression.
    Liang Z, Ge Y, Li J, Bai Y, Xiao Z, Yan R, An G, Zhang D.
    J Cancer Res Clin Oncol; 2024 Jul 09; 150(7):342. PubMed ID: 38980538
    [Abstract] [Full Text] [Related]

  • 7. Compound C induces protective autophagy in human cholangiocarcinoma cells via Akt/mTOR-independent pathway.
    Zhao X, Luo G, Cheng Y, Yu W, Chen R, Xiao B, Xiang Y, Feng C, Fu W, Duan C, Yao F, Xia X, Tao Q, Wei M, Dai R.
    J Cell Biochem; 2018 Jul 09; 119(7):5538-5550. PubMed ID: 29384220
    [Abstract] [Full Text] [Related]

  • 8. Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells.
    Wang F, Wang Q, Zhou ZW, Yu SN, Pan ST, He ZX, Zhang X, Wang D, Yang YX, Yang T, Sun T, Li M, Qiu JX, Zhou SF.
    Drug Des Devel Ther; 2015 Jul 09; 9():537-60. PubMed ID: 25632222
    [Abstract] [Full Text] [Related]

  • 9. Modulatory role of garlicin in migration and invasion of intrahepatic cholangiocarcinoma via PI3K/AKT pathway.
    Xie K, Nian J, Zhu X, Geng X, Liu F.
    Int J Clin Exp Pathol; 2015 Jul 09; 8(11):14028-33. PubMed ID: 26823715
    [Abstract] [Full Text] [Related]

  • 10. Puquitinib mesylate (XC-302) induces autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells.
    Wang KF, Yang H, Jiang WQ, Li S, Cai YC.
    Int J Mol Med; 2015 Dec 09; 36(6):1556-62. PubMed ID: 26499488
    [Abstract] [Full Text] [Related]

  • 11. Role of PI3K/Akt/mTOR pathway-mediated macrophage autophagy in affecting the phenotype transformation of lung fibroblasts induced by silica dust exposure.
    DU Y, Huang F, Guan L, Zeng M.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Aug 28; 48(8):1152-1162. PubMed ID: 37875355
    [Abstract] [Full Text] [Related]

  • 12. Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells.
    Pan ST, Qin Y, Zhou ZW, He ZX, Zhang X, Yang T, Yang YX, Wang D, Qiu JX, Zhou SF.
    Drug Des Devel Ther; 2015 Aug 28; 9():1601-26. PubMed ID: 25834400
    [Abstract] [Full Text] [Related]

  • 13. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F, Li H, Yan XG, Zhou ZW, Yi ZG, He ZX, Pan ST, Yang YX, Wang ZZ, Zhang X, Yang T, Qiu JX, Zhou SF.
    Drug Des Devel Ther; 2015 Aug 28; 9():575-601. PubMed ID: 25632225
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
    Ewald F, Nörz D, Grottke A, Hofmann BT, Nashan B, Jücker M.
    Invest New Drugs; 2014 Dec 28; 32(6):1144-54. PubMed ID: 25152244
    [Abstract] [Full Text] [Related]

  • 20. Effect of Gubenyiliu formula II and its disassembled prescriptions on cell autophagy in breast cancer through PI3K/AKT/mTOR pathway.
    Chen X, Jin G, Luo H, Zhou L.
    Anticancer Drugs; 2023 Jul 01; 34(6):725-734. PubMed ID: 36727774
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.